Navigation Links
Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Date:6/27/2008

Exelixis Generated 10 IND Compounds and Received over $235 Million

SOUTH SAN FRANCISCO, Calif., June 27 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that the company and GlaxoSmithKline, Inc. (NYSE: GSK) will bring their six-year collaboration to a successful conclusion on October 27, 2008, as scheduled. Under the terms of the collaboration, GSK has the right to select up to two of the compounds in the collaboration for further development and commercialization. GSK previously selected XL880 and will be able to choose one additional compound from among XL184, XL281, XL228, XL820, and XL844. Exelixis will have the right to develop and commercialize compounds not selected by GSK, either alone or in collaboration with partners. As a result of the conclusion of the collaboration, Exelixis' exclusivity obligations will be limited to the compounds selected by GSK. Exelixis will have the right to perform additional discovery, development, and commercialization efforts against any collaboration target or compound that does not infringe upon the intellectual property associated with compounds selected by GSK for further development and commercialization.

"This collaboration represents a successful alliance that has truly benefited both companies. With the selection of GSK089 (formerly XL880) and potentially one other compound, GSK has been able to strengthen its oncology pipeline. I am enthusiastic about the compounds remaining in the collaboration, and continue to be impressed by Exeli
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has ... "Neuroprotection - Drugs, Markets and Companies" ... the role of neuroprotection in acute disorders such ... as well as in chronic diseases such as ... of damage to neural tissues are similar in ...
(Date:5/28/2015)... 28, 2015 Celsion Corporation (the "Company") (NASDAQ: ... commitments from two institutional healthcare investors to purchase an ... stock in an at-the-market registered direct offering and a ... The Company entered into a definitive purchase ... agreed to sell an aggregate of 3,000,000 shares of ...
(Date:5/28/2015)... 2015 DryLet, LLC a biotechnology ... such as animal waste reduction, bioremediation, wastewater treatment, ... wastewater treatment plants and restaurant kitchen settings, announced ... Expo, June 3-5 in Des Moines, Iowa. , ... Wall Street Journal article because of its industry-leading ...
(Date:5/28/2015)... 28, 2015  PDS Biotechnology Corp. announces preliminary ... targeting HPV-16, has generated strong T-cell responses in ... cancer is treated by surgical removal of lesions ... non-surgical alternative. Results show that it primes and ... target, and kill precancerous and cancerous cells that ...
Breaking Biology Technology:Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2
... OREX ), a biopharmaceutical company focused on ... Patent and Trademark Office,(USPTO) has issued a patent for ... (U.S. Patent No. 7,462,626), which provides,coverage for Contrave(R), the ... trials. , The patent broadly ...
... BELGIUM, Wis., Jan. 5 Mach One Corporation,(Pink Sheets: ... a positive long term benefit to the agricultural and ... non-binding letter of,intent dated December 30, 2008 related to ... BioPharm) (the "Seller" or "BioPharm") to,acquire all of the ...
... of Norton & Associates with Divisions in NORTECH ... Carbon Credit Today. The group,s announcement of a ... private equity land investments and the acquisition funding ... commercial market conditions, Norton & Associates Inc. provides ...
Cached Biology Technology:Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R) 2Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R) 3Mach One Corporation Enters Letter of Intent 2Norton & Associates Inc. Adds $3bnUSD Commercial Real Estate Investment P & L Management Holding Group; US Property Portfolio Inc. 2
(Date:5/8/2015)... Calif. , May 8, 2015 Synaptics Inc. ... solutions, today announced that members of the executive management team ... Morgan 43rd Annual Technology, Media and Telecom Conference Date: ... Hotel in Boston, MA ... 27, 2015 Time: 2:45pm ET Location: The New York Palace ...
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... Washington, D.C. (October 5, 2010) -- Carbon nanotubes -- ... in diameter -- have many potential uses in nanotechnology, ... of nanotubes depend on their structure, and scientists as ... determined during the initial formation -- or growth -- ...
... BOZEMAN, Mont. -- Montana State University researchers have discovered a ... geothermal vents at the bottom of Yellowstone Lake. A ... in an area where the water is inky black, about ... poisons, the researchers reported in the September issue of Geobiology. ...
... toxic pollution falling onto Puget Sound,s waters has decreased ... below earlier estimates, according to a region-wide study. Despite ... like Tacoma still have the Puget,s Sound,s highest air-deposited ... of Energy,s Pacific Northwest National Laboratory and Texas A&M ...
Cached Biology News:The effects of hydrogen on growing carbon nanotubes 2Montana State team finds rare oasis of life on floor of Yellowstone Lake 2Montana State team finds rare oasis of life on floor of Yellowstone Lake 3Montana State team finds rare oasis of life on floor of Yellowstone Lake 4The sky is falling (less) onto Puget Sound 2The sky is falling (less) onto Puget Sound 3The sky is falling (less) onto Puget Sound 4
BAFF-R (CT) BR3 Affinity Purified Polyclonal Antibody...
HOXC11 Antibody...
HOXC11 Antibody...
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: